Trial reportHealth technology assessment (Winchester, England)2025
Methylphenidate versus placebo for fatigue in patients with advanced cancer: the MePFAC randomised controlled trial.
Trial report in Health technology assessment (Winchester, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline for Medication Management of Distressing Symptoms in Older Patients Receiving End-of-Life Palliative Care.Journal of evidence-based medicine · 2026Guideline
- The ICaRAS randomised controlled trial: Intravenous iron to treat anaemia in people with advanced cancer - feasibility of recruitment, intervention and delivery.Palliative medicine · 2023Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous meta-analyses suggested methylphenidate may be effective for cancer-related fatigue. Trial design: Phase III, parallel-group, randomised, double-blind, placebo-controlled trial. Methods: Participants were adults with advanced cancer with cancer-related fatigue receiving palliative care at 17 palliative care services in England between June 2018 and April 2023. Principal exclusions: Pregnancy; glaucoma; pheochromocytoma; planned general anaesthesia; hyperthyroidism; severe psychiatric disorders; hypertension; severe cardiovascular disorders; cerebrovascular disorders; anaemia; thrombocytopenia; leucopenia; infection; renal or liver impairment; concomitant clonidine, warfarin, monoamine oxidase inhibitors or modafinil; alcohol or drug dependency; epilepsy. Interventions: Methylphenidate 5 mg tablets or matching placebo. Starting at 1 tablet twice daily, titrated over 6 weeks to a maximum of 12 tablets/day. Objective: To estimate clinical effectiveness of methylphenidate versus placebo for cancer-related fatigue in patients receiving palliative care. Primary outcome: Fatigue at 6 (± 2) weeks measured using the Functional Assessment of Chronic Illness Therapy - Fatigue Scale score. Secondary outcomes were fatigue at other time points; quality of life, adverse events, activities of daily living; appetite; anxiety; depression; patient satisfaction; survival and need for other medication. Randomisation: Computer-generated 1 : 1 randomisation, stratified by centre, concomitant treatment, depression and initial fatigue score. Blinding: Participants and outcome assessors were blinded to group assignment. Results: Eighty-four were allocated to methylphenidate and 78 to placebo. Recruitment: : Study completed. Numbers analysed: Seventy-five in methylphenidate group and 72 in placebo group were included in analysis of primary outcome. Outcome: There was no statistically or clinically significant difference in primary outcome between groups. Functional Assessment of Chronic Illness Therapy - Fatigue Scale scores were 1.97 points (95% confidence interval -0.95 to 4.90; Harms: There were 25 serious adverse events in 20 participants receiving methylphenidate and 25 serious adverse events among 16 participants receiving placebo. There were no suspected unexpected serious adverse reactions. There were no statistically significant differences in deaths occurring within 75 days of randomisation (2 participants in placebo group and 6 participants in the methylphenidate group; Fisher's exact Limitations: Participants were highly selected due to multiple exclusion criteria. The choice of 5-point difference in Functional Assessment of Chronic Illness Therapy - Fatigue Scale score as clinically significant primary outcome may be debated. Conclusions: Methylphenidate did not reduce fatigue severity in patients with advanced cancer at 6 (± 2) weeks but was safe and well tolerated. Future work: Further trials of methylphenidate for fatigue in patients with advanced cancer receiving palliative care are not recommended. There may be scope for further studies in different populations or for different indications. Funding: This synopsis presents independent research funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme as award number 15/46/02.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.